Vion Presents Preclinical Data on Its Novel Sulfonyl Hydrazine Prodrug Technology at the American Association for Cancer Research Meeting
(PR Newswire)...VNP40101M also exhibited excellent penetration across the blood brain barrier in mice, and a high degree of antitumor activity against intra-cranially implanted leukemia cells.......The latter distinguishes VNP40101M from many anticancer agents that have difficulty penetrating into the brain, a site where primary tumors can occur and a common site of metastases for several other solid tumors....- Mar 26 8:32 AM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/prnews/010326/hsm023.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines